When stratified by PD-L1 levels, even patients with high PD-L1 expression (TPS 50–100%) did not derive as much benefit from chemoIO therapy in EGFR-mutant lung cancers, which is especially disappointing when compared to high PDL1 EGFR-wildtype tumors. This evidence concerns the gene EGFR and lung carcinoma.